IBDEI0KR ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9681,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9681,1,2,0)
 ;;=2^Intravitreal Inj of Eye Drug
 ;;^UTILITY(U,$J,358.3,9681,1,3,0)
 ;;=3^67028
 ;;^UTILITY(U,$J,358.3,9682,0)
 ;;=J9035^^43^492^3^^^^1
 ;;^UTILITY(U,$J,358.3,9682,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9682,1,2,0)
 ;;=2^Bevacizumab Inj 10mg
 ;;^UTILITY(U,$J,358.3,9682,1,3,0)
 ;;=3^J9035
 ;;^UTILITY(U,$J,358.3,9683,0)
 ;;=J2778^^43^492^6^^^^1
 ;;^UTILITY(U,$J,358.3,9683,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9683,1,2,0)
 ;;=2^Ranibizumab Inj per 0.1mg
 ;;^UTILITY(U,$J,358.3,9683,1,3,0)
 ;;=3^J2778
 ;;^UTILITY(U,$J,358.3,9684,0)
 ;;=J3301^^43^492^7^^^^1
 ;;^UTILITY(U,$J,358.3,9684,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9684,1,2,0)
 ;;=2^Triamcinolone Acetonide Inj per 10mg
 ;;^UTILITY(U,$J,358.3,9684,1,3,0)
 ;;=3^J3301
 ;;^UTILITY(U,$J,358.3,9685,0)
 ;;=J0178^^43^492^1^^^^1
 ;;^UTILITY(U,$J,358.3,9685,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9685,1,2,0)
 ;;=2^Aflibercept Inj 1mg
 ;;^UTILITY(U,$J,358.3,9685,1,3,0)
 ;;=3^J0178
 ;;^UTILITY(U,$J,358.3,9686,0)
 ;;=C9257^^43^492^2^^^^1
 ;;^UTILITY(U,$J,358.3,9686,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9686,1,2,0)
 ;;=2^Bevacizumab Inj 0.25 mg
 ;;^UTILITY(U,$J,358.3,9686,1,3,0)
 ;;=3^C9257
 ;;^UTILITY(U,$J,358.3,9687,0)
 ;;=J9400^^43^492^8^^^^1
 ;;^UTILITY(U,$J,358.3,9687,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9687,1,2,0)
 ;;=2^ZIV-Aflibercept 1 mg
 ;;^UTILITY(U,$J,358.3,9687,1,3,0)
 ;;=3^J9400
 ;;^UTILITY(U,$J,358.3,9688,0)
 ;;=J7312^^43^492^4^^^^1
 ;;^UTILITY(U,$J,358.3,9688,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9688,1,2,0)
 ;;=2^Dexamethasone Intra Implant
 ;;^UTILITY(U,$J,358.3,9688,1,3,0)
 ;;=3^J7312
 ;;^UTILITY(U,$J,358.3,9689,0)
 ;;=4450F^^43^493^2^^^^1
 ;;^UTILITY(U,$J,358.3,9689,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9689,1,2,0)
 ;;=2^Self-Care Ed Provided to Pt
 ;;^UTILITY(U,$J,358.3,9689,1,3,0)
 ;;=3^4450F
 ;;^UTILITY(U,$J,358.3,9690,0)
 ;;=4177F^^43^493^3^^^^1
 ;;^UTILITY(U,$J,358.3,9690,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9690,1,2,0)
 ;;=2^Talk Pt/Crgvr Re AREDS
 ;;^UTILITY(U,$J,358.3,9690,1,3,0)
 ;;=3^4177F
 ;;^UTILITY(U,$J,358.3,9691,0)
 ;;=4174F^^43^493^1^^^^1
 ;;^UTILITY(U,$J,358.3,9691,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9691,1,2,0)
 ;;=2^Couns Potent Glauc Impct
 ;;^UTILITY(U,$J,358.3,9691,1,3,0)
 ;;=3^4174F
 ;;^UTILITY(U,$J,358.3,9692,0)
 ;;=S0260^^43^494^1^^^^1
 ;;^UTILITY(U,$J,358.3,9692,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9692,1,2,0)
 ;;=2^Outpt H&P for Surgical Procedure
 ;;^UTILITY(U,$J,358.3,9692,1,3,0)
 ;;=3^S0260
 ;;^UTILITY(U,$J,358.3,9693,0)
 ;;=B02.33^^44^495^164
 ;;^UTILITY(U,$J,358.3,9693,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9693,1,3,0)
 ;;=3^Zoster Keratitis
 ;;^UTILITY(U,$J,358.3,9693,1,4,0)
 ;;=4^B02.33
 ;;^UTILITY(U,$J,358.3,9693,2)
 ;;=^5000496
 ;;^UTILITY(U,$J,358.3,9694,0)
 ;;=B02.32^^44^495^163
 ;;^UTILITY(U,$J,358.3,9694,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9694,1,3,0)
 ;;=3^Zoster Iridocyclitis
 ;;^UTILITY(U,$J,358.3,9694,1,4,0)
 ;;=4^B02.32
 ;;^UTILITY(U,$J,358.3,9694,2)
 ;;=^5000495
 ;;^UTILITY(U,$J,358.3,9695,0)
 ;;=B00.52^^44^495^82
 ;;^UTILITY(U,$J,358.3,9695,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9695,1,3,0)
 ;;=3^Herpesviral Keratitis
 ;;^UTILITY(U,$J,358.3,9695,1,4,0)
 ;;=4^B00.52
 ;;^UTILITY(U,$J,358.3,9695,2)
 ;;=^5000474
 ;;^UTILITY(U,$J,358.3,9696,0)
 ;;=B00.51^^44^495^81
 ;;^UTILITY(U,$J,358.3,9696,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9696,1,3,0)
 ;;=3^Herpesviral Iridocyclitis
 ;;^UTILITY(U,$J,358.3,9696,1,4,0)
 ;;=4^B00.51
